Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice
复制标题
DOI：
10.1186/s12967-019-02132-x
复制
发表时间：
2019-11-15
影响因子：
7.4
通讯作者：
Ascierto, Paolo A.
中科院分区：
文献类型：
--
作者：
Cortellini, Alessio;Vitale, Maria G.;Ascierto, Paolo A.
背景在接受PD-1/PD-L1检查点抑制剂治疗的癌症患者中，疲劳是最常见的任何级别的不良事件(18.3%)，也是最常见的3级或更高级别的免疫相关不良事件(IRAE)(0.89%)。方法这项多中心回顾性研究的目的是在临床实践中评估接受PD-1/PD-L1抑制剂治疗的癌症患者早期IR疲劳和延迟IR疲劳与临床结果的相关性。经过12周的里程碑选择，386名患者(74.7%)符合临床结果分析的条件。40.4%为非小细胞肺癌，42.2%为黑色素瘤，15.3%为肾细胞癌，2.1%为其他恶性肿瘤。76例患者(19.7%)出现早期IR疲劳(自治疗开始1个月内)，150例患者(38.9%)出现延迟性IR疲劳。早期IR疲劳与PFS缩短显著相关(HR=2.29[95%CI 1.62-3.22]，p
Background Fatigue was reported as the most common any-grade adverse event (18.3%), and the most common grade 3 or higher immune-related adverse event (irAE) (0.89%) in patients receiving PD-1/PD-L1 checkpoint inhibitors in clinical trial.Methods The aim of this retrospective multicenter study was to evaluate the correlations between "early ir-fatigue", "delayed ir-fatigue", and clinical outcomes in cancer patients receiving PD-1/PD-L1 inhibitors in clinical practice.Results 517 patients were evaluated. After the 12-weeks landmark selection, 386 (74.7%) patients were eligible for the clinical outcomes analysis. 40.4% were NSCLC, 42.2% were melanoma, 15.3% renal cell carcinoma and 2.1% other malignancies. 76 patients (19.7%) experienced early ir-fatigue (within 1 month from treatment commencement), while 150 patients (38.9%) experienced delayed ir-fatigue. Early ir-fatigue was significantly related to shortened PFS (HR=2.29 [95% CI 1.62-3.22], p